| Intranasal insulin to improve developmental delay in children with 22q13 deletion syndrome: an exploratory clinical trial. | |
| | |
MedLine Citation:
|
PMID: 18948358 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The 22q13 deletion syndrome (Phelan-McDermid syndrome) is characterised by a global developmental delay, absent or delayed speech, generalised hypotonia, autistic behaviour and characteristic phenotypic features. Intranasal insulin has been shown to improve declarative memory in healthy adult subjects and in patients with Alzheimer disease. AIMS: To assess if intranasal insulin is also able to improve the developmental delay in children with 22q13 deletion syndrome. METHODS: We performed exploratory clinical trials in six children with 22q13 deletion syndrome who received intranasal insulin over a period of 1 year. Short-term (during the first 6 weeks) and long-term effects (after 12 months of treatment) on motor skills, cognitive functions, or autonomous functions, speech and communication, emotional state, social behaviour, behavioural disorders, independence in daily living and education were assessed. RESULTS: The children showed marked short-term improvements in gross and fine motor activities, cognitive functions and educational level. Positive long-term effects were found for fine and gross motor activities, nonverbal communication, cognitive functions and autonomy. Possible side effects were found in one patient who displayed changes in balance, extreme sensitivity to touch and general loss of interest. One patient complained of intermittent nose bleeding. CONCLUSIONS: We conclude that long-term administration of intranasal insulin may benefit motor development, cognitive functions and spontaneous activity in children with 22q13 deletion syndrome. |
| | |
Authors:
|
H Schmidt; W Kern; R Giese; M Hallschmid; A Enders |
Related Documents
:
|
7813158 - The craniofacial dysostosis syndromes. current reconstructive strategies. 21965948 - Mitral valve prolapse syndrome and its association with anxiety and panic states. 839508 - Crossed asymmetry in russell-silver syndrome. 11861708 - The gerstmann syndrome in alzheimer's disease. 18064948 - Ocular migraine and antiphospholipid antibodies--where we stand? 8172158 - Familial visceral neuropathy as part of a diffuse neuronal syndrome: four fatal cases i... |
Publication Detail:
|
Type: Clinical Trial; Journal Article Date: 2008-10-23 |
Journal Detail:
|
Title: Journal of medical genetics Volume: 46 ISSN: 1468-6244 ISO Abbreviation: J. Med. Genet. Publication Date: 2009 Apr |
Date Detail:
|
Created Date: 2009-04-09 Completed Date: 2009-05-28 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 2985087R Medline TA: J Med Genet Country: England |
Other Details:
|
Languages: eng Pagination: 217-22 Citation Subset: IM |
Affiliation:
|
Dr von Hauner Children's Hospital, University of Munich, Lindwurmstr. 4, 80337 Munich, Germany. heinrich.schmidt@med.uni-muenchen.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Intranasal Child Child, Preschool Chromosome Deletion* Chromosome Disorders / drug therapy, genetics, pathology Chromosomes, Human, Pair 22 / genetics* Cognition / drug effects Developmental Disabilities / drug therapy*, genetics, pathology Female Humans Hypoglycemic Agents / administration & dosage, therapeutic use Infant Insulin / administration & dosage, therapeutic use* Male Motor Skills / drug effects Syndrome Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Hypoglycemic Agents; 11061-68-0/Insulin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Novel transglutaminase-1 mutations and genotype-phenotype investigations of 104 patients with autoso...
Next Document: Molecular characterization of nucleocytosolic O-GlcNAc transferases of Giardia lamblia and Cryptospo...